RxDoctor Payments Data

Raluca Ionescu, MD

Internal Medicine · Spokane, WANPI 1497721211

Payments from drug & device makers

$784in general payments, 2019–2025

Across 10 payments — averaging $78.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$243
  • Inspire Medical Systems, Inc.$122
  • Boehringer Ingelheim$118
  • AbbVie$105
  • Boston Scientific$99
  • Novo Nordisk$74
  • plus $23 from 1 others

What the payments were for

  • Food & beverage$76197%
  • Education$233%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$784 in reported general payments places this provider in the 85th percentile of 2,038 internal medicine providers in Washington.

See all internal medicine providers in Washington

Medicare billing

Part B allowed, 2024
$225,685
Medicare patients
379
Services billed
4,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban121$137,841
JardianceEmpagliflozin86$129,064
OzempicSemaglutide72$82,691
MounjaroTirzepatide63$78,520
XareltoRivaroxaban52$52,352
TrulicityDulaglutide36$41,066
MyrbetriqMirabegron25$24,825
Spiriva HandihalerTiotropium Bromide22$22,291
Bydureon BciseExenatide Microspheres11$13,966
RybelsusSemaglutide13$13,122
Incruse ElliptaUmeclidinium Bromide20$12,060
Gabapentin304$10,427
Repatha SureclickEvolocumab12$10,341
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$9,229
Advair HfaFluticasone Propion/Salmeterol16$8,850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$137,841121 claims
Boehringer IngelheimJardiance$118$129,06486 claims
Lilly USA, LLCMounjaro, Trulicity$243$119,58699 claims
Novo NordiskOzempic, Rybelsus$74$95,81385 claims
AbbVieSynthroid$105$1,87632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,038 internal medicine providers in Washington.

Other internal medicine in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →